EXACT Sciences Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30063P1057
USD
101.13
-0.07 (-0.07%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About EXACT Sciences Corp. stock-summary
stock-summary
EXACT Sciences Corp.
Pharmaceuticals & Biotechnology
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Company Coordinates stock-summary
Company Details
5505 ENDEAVOR LANE , MADISON WI : 53719
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 136 Schemes (59.56%)

Foreign Institutions

Held by 345 Foreign Institutions (19.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kevin Conroy
Chairman of the Board, President, Chief Executive Officer
Ms. Shacey Petrovic
Director
Mr. Thomas Carey
Independent Director
Mr. James Doyle
Independent Director
Mr. Pierre Jacquet
Independent Director
Mr. Daniel Levangie
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
811 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,202 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.61

stock-summary
Return on Equity

-6.25%

stock-summary
Price to Book

4.13